| The US is communicating regularly with India in bilateral and multilateral channels to discuss the supply of Covid-19 vaccines and inquire about its timeline for restarting vaccine exports. “Vaccinating as much of the developing world, as quickly as possible, is in America’s vital interest, because the uncontrolled spread of the virus inevitably produces more dangerous variants,” an Axios report said. |
The United States has been pushing India to restart vaccine exports as it looks to stem the global spread of the Covid pandemic.
The US is communicating regularly with India in bilateral and multilateral channels to discuss the supply of Covid-19 vaccines and inquire about its timeline for restarting vaccine exports, a senior Biden administration official told Reuters.
The supply of Covid vaccines will also be one of the key topics of discussion during the first in-person Quad leadership meeting in US on September 24. Quad is a multilateral alliance of US, India, Australia and Japan.
During their virtual meeting in March this year, the Quad leaders had agreed to work closely on boosting Covid-19 vaccine supply.
However, the initiative was stalled after India was struck by the deadly second wave of the virus.
Since then, India’s vaccine exports took a major hit as the country sought to prioritise immunisation of its population of over 1.3 billion people.
According to Axios, the Biden administration is now looking to push Modi to renew vaccine supply to the world through the global Covax initiative since it wants to mitigate the international spread of the virus.
“Vaccinating as much of the developing world, as quickly as possible, is in America’s vital interest, because the uncontrolled spread of the virus inevitably produces more dangerous variants,” the Axios report said.
“Washington was staying in close touch with India and other Quad partners about the vaccine partnership, and any factors that may affect this project or global vaccine supply, but those discussions were not tied to a specific summit or engagement,” the US official said.
The official noted that Washington had diverted its own supply of raw materials for vaccine production to India in April, given its urgent needs, and global vaccine supply remained a key bottleneck to ending the pandemic.
“We commend India for being one of the largest manufacturers for safe and effective COVID-19 vaccines globally, and we note that COVAX and the world rely heavily on India’s contributions,” the official said. “It’s important for the United States to engage all our allies and partners on these matters so we can take the necessary actions to end this pandemic together.“
However, while US is pushing India to kickstart its vaccine exports, it had stalled its own vaccine exports for months to prioritise shots for its population under the “America First” policy.
Donald Trump’s tariffs of 50% have come into force on most US imports from India. India’s giant generic pharmaceuticals sector and its electronics and petroleum products are exempt from the tariffs. Aluminium, steel and copper remain at 25%, but job-heavy sectors such as textiles, jewellery, seafood and leather are squarely in the line of fire.
The European Chemicals Agency (ECHA) has published the updated proposal to restrict per- and polyfluoroalkyl substances (PFAS) under the EU’s chemicals regulation, REACH. The update has been prepared by the authorities from Denmark, Germany, the Netherlands, Norway and Sweden, who submitted the initial proposal in January 2023.
Most chemicals exported from the 27 member countries of the European Union into the US will be subject to a 15% tariff on top of their selling prices under an agreement signed on July 27 between the US and the European Commission.
We’re thrilled to announce a new strategic alliance between ExSyn, Exim-Indis and simABs, a leading EU-based biologics manufacturer known for its patented continuous flow technology in antibody production.
The global trade landscape is undergoing significant changes following the announcement of new reciprocal tariffs by the United States government. Recent developments indicate significant shifts in global trade dynamics, with key policy adjustments, ongoing negotiations, and evolving logistics patterns. Below is a summary of the latest developments.
In January 2025, the US FDA published a draft regulatory guidance entitled “The Considerations for Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products”.
The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.
In the quest for increased sustainability, a lot has been made of the potential to use bio-based raw materials, captured CO2 and recycled plastics as raw materials for new chemicals. But what about using biotech processes to manufacture chemicals? Could it offer a more sustainable alternative to traditional petrochemical processing, and be more amenable to biobased raw materials?
High duties on imports from Canada, Mexico and China raise problems for international supply chains.